Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone

Journal of Urology

Volumn 173, Issue 6, 2005, Pages 1947-1952

  Scholz, Mark ^a   Jennrich, Robert ^b   Strum, Stephen ^a   Brosman, Stanley ^a   Johnson, Henry ^a   Lam, Richard ^b  

^a Los Angeles ^*

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ketoconazole; Prostate specific antigen; Prostatic neoplasms; Survival

Indexed keywords

ANDROGEN; HYDROCORTISONE; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG MEGADOSE; FATIGUE; FOLLOW UP; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; LASSITUDE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; REVIEW; SURVIVAL TIME;

EID: 18744399321     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000158449.83022.40     Document Type: Article

References (20)

1. Johnson, D. E., Babaian, R. J., von Eschenbach, A. C., Wishnow, K. I. and Tenney, D.: Ketoconazole therapy for hormonally refractive metastatic prostate cancer. Urology, 31: 132, 1988
2. Tapazoglou, E., Subramanian, M. G., Al-Sarraf, M., Kresge, C. and Decker, D. A.: High-dose ketoconazole therapy in patients with metastatic prostate cancer. Am J Clin Oncol, 9: 369, 1986
3. Trachtenberg, J. and Pont, A.: Ketoconazole therapy for advanced prostate cancer. Lancet, 2: 433, 1984
4. Aabo, K., Kjaer, M. and Hansen, H. H.: High-dose ketoconazole to untreated stage D prostate cancer. Eur J Cancer Clin Oncol, 24: 431, 1988
5. Gerber, G. S. and Chodak, G. W.: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer. J Urol, 144: 1177, 1990
6. Trump, D. L., Havlin, K. H., Messing, E. M., Cummings, K. B., Lange, P. H. and Jordan, V. C.: High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol, 7: 1093, 1989
7. Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M. et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol, 17: 3461, 1999
8. Small, E. J., Baron, A. and Bok, R.: Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer, 80: 1755, 1997
9. Small, E. J. and Vogelzang, N. J.: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol, 15: 382, 1997
10. Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V., Schwartz, M. and Fossa, S. D.: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol, 11: 607, 1993
11. Smith, D. C., Dunn, R. L., Strawderman, M. S. and Pienta, K. J.: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol, 16: 1835, 1998
12. Scher, H. I. and Kelly, W. K.: Editorial: States and state transitions are all that really matter. J Urol, 168: 2451, 2002
13. Small, E. J., McMillan, A., Meyer, M., Chen, L., Slichenmyer, W. J., Lenehan, P. F. et al: Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol, 19: 1304, 2001
14. Scher, H. I., Kelly, W. M., Zhang, Z. F., Ouyang, P., Sun, M., Schwartz, M. et al: Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst, 91: 244, 1999
15. Scher, H. I. and Kelly, W. K.: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol, 11: 1566, 1993
16. Small, E. J. and Srinivas, S.: The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer, 76: 1428, 1995
17. Small, E. J., Halabi, S., Picus, L., Dawson, N., Chen, Y. and Vogelzang, N. J.: A prospective trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients: result of CALBG 9583. Proc Am Soc Clin Oncol, 20: 695, 2001
18. Small, E. J., Baron, A. D., Fippin, L. and Apodaca, D.: Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol, 157: 1204, 1997
19. Harris, K. A., Small, E. J., Frohlich, M. W., Bok, R., Randall, M. and Kakefuda, M.: Prospective trial of low dose ketoconazole therapy in patients with androgen-independent prostate cancer. Proc Am Soc Clin Oncol, 20: 2419, 2001
20. Segal, R. J., Reid, R. D., Courneya, K. S., Malone, S. C., Parliament, M. B., Scott, C. G. et al: Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol, 21: 1653, 2003